Raffaele Migliore Email

Associate VP, Clinical Development . Intra-Cellular Therapies

Current Roles

Employees:
541
Revenue:
$70.6M
About
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications. Use link below for a listing of Job Opportunities: https://www.linkedin.com/jobs/search/keywords=intra-cellular%20therapies&location=United%20States&locationId=us%3A0
Intra-Cellular Therapies Address
430 East 29th Street
New York, NY
United States
Intra-Cellular Therapies Email

Past Companies

Intra-Cellular TherapiesAssociate Vice President, Clinical Development
Intra-Cellular TherapiesExecutive Director, Clinical Development
AllerganExecutive Director, Clinical Development

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.